Literature DB >> 33606578

Vaccinia virus-based vector against infectious diseases and tumors.

Ziling Zhang1, Lanlan Dong1, Chen Zhao1, Peiyong Zheng2, Xiaoyan Zhang1,3, Jianqing Xu1,3.   

Abstract

Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases. It also finds a new place in oncolytic therapy. Here we provide a brief review of the history, current status, and future prospect of vaccinia virus-based vaccine and oncolytic virus. New advancements, including a single vaccine targeting multiple viruses, strategies of arming vaccinia viruses to enhance anti-tumor activity, the promise and challenge of combining vaccinia-based virotherapy with immunotherapy, are discussed as special focus.

Entities:  

Keywords:  Tiantan strain; Vaccinia virus; oncolytic virus; tumor; vaccine vector

Mesh:

Year:  2021        PMID: 33606578      PMCID: PMC8115763          DOI: 10.1080/21645515.2020.1840887

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  Airborne transmission of influenza A/H5N1 virus between ferrets.

Authors:  Sander Herfst; Eefje J A Schrauwen; Martin Linster; Salin Chutinimitkul; Emmie de Wit; Vincent J Munster; Erin M Sorrell; Theo M Bestebroer; David F Burke; Derek J Smith; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

2.  Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Authors:  Glenda E Gray; Ying Huang; Nicole Grunenberg; Fatima Laher; Surita Roux; Erica Andersen-Nissen; Stephen C De Rosa; Britta Flach; April K Randhawa; Ryan Jensen; Edith M Swann; Linda-Gail Bekker; Craig Innes; Erica Lazarus; Lynn Morris; Nonhlanhla N Mkhize; Guido Ferrari; David C Montefiori; Xiaoying Shen; Sheetal Sawant; Nicole Yates; John Hural; Abby Isaacs; Sanjay Phogat; Carlos A DiazGranados; Carter Lee; Faruk Sinangil; Nelson L Michael; Merlin L Robb; James G Kublin; Peter B Gilbert; M Juliana McElrath; Georgia D Tomaras; Lawrence Corey
Journal:  Sci Transl Med       Date:  2019-09-18       Impact factor: 17.956

3.  First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Authors:  Herbert J Zeh; Stephanie Downs-Canner; J Andrea McCart; Zong Sheng Guo; Uma N M Rao; Lekshmi Ramalingam; Stephen H Thorne; Heather L Jones; Pawel Kalinski; Eva Wieckowski; Mark E O'Malley; Manijeh Daneshmand; Kang Hu; John C Bell; Tae-Ho Hwang; Anne Moon; Caroline J Breitbach; David H Kirn; David L Bartlett
Journal:  Mol Ther       Date:  2014-10-08       Impact factor: 11.454

4.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

5.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors:  Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

6.  A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice.

Authors:  Patricia Pérez; María Q Marín; Adrián Lázaro-Frías; Nereida Jiménez de Oya; Ana-Belén Blázquez; Estela Escribano-Romero; Carlos Óscar S Sorzano; Javier Ortego; Juan-Carlos Saiz; Mariano Esteban; Miguel A Martín-Acebes; Juan García-Arriaza
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

7.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 8.  HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.

Authors:  Sonia Pernas; Sara M Tolaney
Journal:  Ther Adv Med Oncol       Date:  2019-03-19       Impact factor: 8.168

9.  Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.

Authors:  Till Koch; Christine Dahlke; Anahita Fathi; Alexandra Kupke; Verena Krähling; Nisreen M A Okba; Sandro Halwe; Cornelius Rohde; Markus Eickmann; Asisa Volz; Thomas Hesterkamp; Alen Jambrecina; Saskia Borregaard; My L Ly; Madeleine E Zinser; Etienne Bartels; Joseph S H Poetsch; Reza Neumann; Robert Fux; Stefan Schmiedel; Ansgar W Lohse; Bart L Haagmans; Gerd Sutter; Stephan Becker; Marylyn M Addo
Journal:  Lancet Infect Dis       Date:  2020-04-21       Impact factor: 25.071

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  7 in total

Review 1.  The Role of Viral RNA Degrading Factors in Shutoff of Host Gene Expression.

Authors:  Léa Gaucherand; Marta Maria Gaglia
Journal:  Annu Rev Virol       Date:  2022-06-07       Impact factor: 14.263

Review 2.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

3.  Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.

Authors:  María M Lorenzo; Aitor Nogales; Kevin Chiem; Rafael Blasco; Luis Martínez-Sobrido
Journal:  Microbiol Spectr       Date:  2022-05-18

Review 4.  Antagonism of Protein Kinase R by Large DNA Viruses.

Authors:  Annabel T Olson; Stephanie J Child; Adam P Geballe
Journal:  Pathogens       Date:  2022-07-12

5.  Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.

Authors:  Xiaoling Cao; Junjie Zai; Qingzhen Zhao; Lilan Xie; Yaoming Li
Journal:  Vaccine       Date:  2022-08-29       Impact factor: 4.169

6.  Efficient Method for Generating Point Mutations in the Vaccinia Virus Genome Using CRISPR/Cas9.

Authors:  Laetitia Boutin; Estelle Mosca; Frédéric Iseni
Journal:  Viruses       Date:  2022-07-18       Impact factor: 5.818

7.  A novel virotherapy encoding human interleukin-7 improves ex vivo T lymphocyte functions in immunosuppressed patients with septic shock and critically ill COVID-19.

Authors:  Morgane Crausaz; Guillaume Monneret; Filippo Conti; Anne-Claire Lukaszewicz; Jean-Baptiste Marchand; Perrine Martin; Geneviève Inchauspé; Fabienne Venet
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.